Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study

• DOI: 10.3389/fcvm.2024.1298346
• Publication Date: 2024-01-15T04:19:27Z
• Authors: Martin Petter Høy...; Rolf Busund; Assami Rösner; Didrik Kjønås
• Keywords: Single Center; Demographics

Background Treatment of severe aortic stenosis with transcatheter valve implantation (TAVI) was introduced in 2002. Since then, TAVI has become the primary treatment approach worldwide for advanced-age patients and younger comorbidities. We aimed to evaluate changes patient demographics, complications, mortality rates within 13 years. Methods This retrospective observational study included 867 who underwent at University Hospital North Norway Tromsø from 2008 2021. The 13-year period divided into 1 (2008–2012), 2 (2013–2017), 3 (2018–2021). objective periprocedural (30 days), early (30–365 late (>365 days) between periods. secondary by sex age groups: <70 years, 70–79 80–89 ≥90 Results periods 1, 2, were 10.3%, 2.9%, 1.2%, respectively ( P < 0.001). 5.6%, 5.8%, 6.5%, respectively. No significant differences observed or group (<70, 70–79, years) a median survival 5.3–5.6 aged years 4.0 = 0.018). Conclusion Our findings indicate that most are octogenarians, burden their comorbidities should be highly considered compared when evaluating procedural outcomes. As incidence complications related decreased, permanent pacemaker remain high. Important advancements diagnostics, technology, techniques have improved rates; however, remains unchanged poses clinical challenge needs addressed future.